These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 16172283)

  • 1. Levels of hematopoiesis inhibitor N-acetyl-seryl-aspartyl-lysyl-proline partially explain the occurrence of anemia in heart failure.
    van der Meer P; Lipsic E; Westenbrink BD; van de Wal RM; Schoemaker RG; Vellenga E; van Veldhuisen DJ; Voors AA; van Gilst WH
    Circulation; 2005 Sep; 112(12):1743-7. PubMed ID: 16172283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition.
    van de Wal RM; Plokker HW; Lok DJ; Boomsma F; van der Horst FA; van Veldhuisen DJ; van Gilst WH; Voors AA
    Int J Cardiol; 2006 Jan; 106(3):367-72. PubMed ID: 16337046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline.
    Azizi M; Rousseau A; Ezan E; Guyene TT; Michelet S; Grognet JM; Lenfant M; Corvol P; Ménard J
    J Clin Invest; 1996 Feb; 97(3):839-44. PubMed ID: 8609242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Congestive heart failure with preserved systolic function in a statewide sample of community hospitals.
    Dauterman KW; Go AS; Rowell R; Gebretsadik T; Gettner S; Massie BM
    J Card Fail; 2001 Sep; 7(3):221-8. PubMed ID: 11561221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are hematinic deficiencies the cause of anemia in chronic heart failure?
    Witte KK; Desilva R; Chattopadhyay S; Ghosh J; Cleland JG; Clark AL
    Am Heart J; 2004 May; 147(5):924-30. PubMed ID: 15131553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin-converting enzyme inhibitors prescription is associated with longer survival among patients hospitalized for congestive heart failure who have preserved systolic function: a long-term follow-up study.
    Grigorian Shamagian L; Roman AV; Ramos PM; Veloso PR; Bandin Dieguez MA; Gonzalez-Juanatey JR
    J Card Fail; 2006 Mar; 12(2):128-33. PubMed ID: 16520261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High plasma level of N-acetyl-seryl-aspartyl-lysyl-proline: a new marker of chronic angiotensin-converting enzyme inhibition.
    Azizi M; Ezan E; Nicolet L; Grognet JM; Ménard J
    Hypertension; 1997 Nov; 30(5):1015-9. PubMed ID: 9369248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Renal failure is an independent predictor of mortality in hospitalized heart failure patients and is associated with a worse cardiovascular risk profile].
    Grigorian Shamagian L; Varela Román A; Pedreira Pérez M; Gómez Otero I; Virgós Lamela A; González-Juanatey JR
    Rev Esp Cardiol; 2006 Feb; 59(2):99-108. PubMed ID: 16540030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-acetyl-seryl-aspartyl-lysyl-proline ameliorates the progression of renal dysfunction and fibrosis in WKY rats with established anti-glomerular basement membrane nephritis.
    Omata M; Taniguchi H; Koya D; Kanasaki K; Sho R; Kato Y; Kojima R; Haneda M; Inomata N
    J Am Soc Nephrol; 2006 Mar; 17(3):674-85. PubMed ID: 16452498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency.
    Toblli JE; Lombraña A; Duarte P; Di Gennaro F
    J Am Coll Cardiol; 2007 Oct; 50(17):1657-65. PubMed ID: 17950147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The interaction between heart failure and other heart diseases, renal failure, and anemia.
    Silverberg DS; Wexler D; Iaina A; Schwartz D
    Semin Nephrol; 2006 Jul; 26(4):296-306. PubMed ID: 16949468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantification of N-acetyl-seryl-aspartyl-lysyl-proline in hemodialysis patients administered angiotensin-converting enzyme inhibitors by stable isotope dilution liquid chromatography-tandem mass spectrometry.
    Inoue K; Ikemura A; Tsuruta Y; Watanabe K; Tsutsumiuchi K; Hino T; Oka H
    J Pharm Biomed Anal; 2011 Mar; 54(4):765-71. PubMed ID: 21074346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of N-acetyl-seryl-aspartyl-lysyl-proline on DNA and collagen synthesis in rat cardiac fibroblasts.
    Rhaleb NE; Peng H; Harding P; Tayeh M; LaPointe MC; Carretero OA
    Hypertension; 2001 Mar; 37(3):827-32. PubMed ID: 11244003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence and prognostic significance of anemia in patients with congestive heart failure treated with standard vs high doses of enalapril.
    Terrovitis JV; Anastasiou-Nana MI; Alexopoulos GP; Tsolakis EJ; Margari ZJ; Drakos SG; Tsagalou EP; Papazoglou P; Efentakis S; Nanas JN
    J Heart Lung Transplant; 2006 Mar; 25(3):333-8. PubMed ID: 16507428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of high- versus low-tissue affinity ACE-inhibitor treatment on circulating aldosterone levels in patients with chronic heart failure.
    Vittorio TJ; Ahuja K; Kasper M; Turalic H; Tseng CH; Jorde UP; Go C
    J Renin Angiotensin Aldosterone Syst; 2007 Dec; 8(4):200-4. PubMed ID: 18205099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-acetyl-seryl-aspartyl-lysyl-proline inhibits DNA synthesis in human mesangial cells via up-regulation of cell cycle modulators.
    Kanasaki K; Haneda M; Sugimoto T; Shibuya K; Isono M; Isshiki K; Araki S; Uzu T; Kashiwagi A; Koya D
    Biochem Biophys Res Commun; 2006 Apr; 342(3):758-65. PubMed ID: 16497271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure and chronic kidney disease.
    Berger AK; Duval S; Manske C; Vazquez G; Barber C; Miller L; Luepker RV
    Am Heart J; 2007 Jun; 153(6):1064-73. PubMed ID: 17540211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High serum enalaprilat in chronic renal failure.
    Elung-Jensen T; Heisterberg J; Kamper AL; Sonne J; Strandgaard S; Larsen NE
    J Renin Angiotensin Aldosterone Syst; 2001 Dec; 2(4):240-5. PubMed ID: 11881130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.